LF15-0195 prevents the induction and inhibits the progression of rat anti-GBM disease  by Tesch, Gregory H. et al.
Kidney International, Vol. 60 (2001), pp. 1354–1365
LF15-0195 prevents the induction and inhibits the progression
of rat anti-GBM disease
GREGORY H. TESCH, PRUDENCE A. HILL, MU WEI, DAVID J. NIKOLIC-PATERSON,
PATRICK DUTARTRE, and ROBERT C. ATKINS
Department of Nephrology and Monash University Department of Medicine, Monash Medical Centre, Clayton, and Department
of Anatomical Pathology, St. Vincent’s Hospital, Fitzroy, Victoria, Australia; and Laboratoires Fournier SA, Daix, France
LF15-0195 prevents the induction and inhibits the progression LF15-0195 is a new immunosuppressant that is struc-
of rat anti-GBM disease. turally related to the spergualin family of drugs that
Background. LF15-0195 is a novel immunosuppressant that includes tresperimus and 15-deoxyspergualin (DSG) [1].is currently in phase II clinical trials for the treatment of vasculi-
This family has been shown to be more effective thantis. This study examined whether LF15-0195 could suppress
the popular immunosuppressants cyclosporine A (CsA),the induction and progression of rat anti-glomerular basement
membrane (anti-GBM) glomerulonephritis. FK506, and rapamycin at prolonging the survival of tissue
Methods. Rapidly progressive glomerulonephritis was in- grafts [2–4] and eliciting fewer adverse side effects [5–7].
duced in primed rats by the administration of anti-GBM serum. The recently developed LF15-0195 has increased meta-In the first experiment, LF15-0195 was given daily by subcuta-
bolic resistance and improved activity compared withneous injection (days 0 to 14) to treat the induction of anti-
other family members, resulting in greater potency [1].GBM disease analyzed at day 14. In a second experiment, rats
received LF15-0195 as an intervention treatment from days 7 In a rat model of heart allotransplantation, a 10-day post-
to 28 (continuous therapy) or days 7 to 12 (pulse therapy) to surgical treatment with LF15-0195 (2.5 mg/kg) achieved
treat the progression of disease assessed at day 28.
a mean survival of 80  30 days, which was significantlyResults. Continuous LF15-0195 treatment during the induc-
better than DSG (6 mg/kg), with a mean survival of 38tion of anti-GBM disease (experiment 1) prevented proteinuria
and loss of renal function, and markedly reduced histological 30 days [1]. LF15-0195 is now being investigated as a
kidney lesions and renal fibrosis. LF15-0195 also reduced kidney potential therapeutic drug for treating both acute and
leukocyte infiltrate, urine excretion of interleukin-1 (IL-1) chronic inflammatory diseases.
and transforming growth factor- (TGF-), and the serum anti-
The immunosuppressive properties of the spergualinbody response, but not kidney deposition of Ig and C3. When
family are known to be different than the ones of theLF15-0195 treatment was initiated at day 7, both continuous
and pulse therapy partially inhibited disease progression by CsA family [8]; however, the mode of action of these
suppressing the loss of renal function, interstitial macrophage spergualin-related drugs is still poorly defined. In vitro
and T-cell accumulation, tubular cell proliferation, and renal and in vivo studies have shown that DSG can suppressfibrosis.
T-cell and macrophage proliferation, cytotoxic T-lym-Conclusion. LF15-0195 prevents the induction and sup-
phocyte (CTL) generation, B-cell maturation, antibodypresses the progression of rat anti-GBM disease through multi-
ple mechanisms of action, suggesting that this drug may have formation, antigen presentation, adhesion molecule ex-
significant therapeutic potential in human glomerulonephritis. pression, and cytokine production [9]. It has been sug-
The similar efficacy of continuous and pulse intervention treat- gested that some of these effects may be due to an inhibi-ment in this model indicates that short-term LF15-0195 treat-
tion of nuclear factor-B activity (NF-B) through drugment may achieve optimal benefit without prolonged bone
marrow suppression. interaction with members of the heat shock protein 70
(HSP-70) family [10, 11]. Recent evidence also indicates
that tresperimus is capable of inducing specific CD4
suppressor cell activity, thereby inhibiting T-cell–med-
iated injury [12].
LF15-0195 may have therapeutic potential for treatingKey words: immunosuppression, vasculitis, progressive glomerular dis-
ease, proteinuria, renal fibrosis, tubular cell proliferation. human glomerulonephritis. In a recent open clinical in-
vestigation, DSG was shown to be effective at sup-Received for publication November 14, 2000
pressing proteinuria in several patients with human pro-and in revised form May 9, 2001
Accepted for publication May 16, 2001 liferative glomerulonephritis, including two with IgA
nephropathy [13]. Animal studies have shown that DSG 2001 by the International Society of Nephrology
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can inhibit the development of both the humoral and were designed to determine whether LF15-0195 treat-
ment could prevent the induction of anti-GBM diseasethe aggressive cellular immune responses associated with
the evolution of rapidly progressive immune-mediated (experiment 1) and the progression of established anti-
GBM disease through continuous treatment (experimentkidney disease [9] and can inhibit the activity of intrinsic
renal cells [14]. DSG treatment during the induction of 2a) and pulse therapy (experiment 2b). LF15-0195 was
administered at a dose that provided maximum immuno-rat anti-GBM disease reduces proteinuria and hematu-
ria, prevents a loss in renal function, and improves the suppression without detrimental side effects for the dura-
tion of the experiment. In experiment 1, groups receivedrenal histology [15]. However, the potential for DSG as
an intervention treatment in this model has not been either saline or LF15-0195 (4 mg/kg/day) from day 0
until being killed at day 14. In experiment 2a, groupsassessed.
The goal of this study was to evaluate whether subcuta- received either saline or LF15-0195 (1 mg/kg/day) from
day 7 until being killed at day 28. An additional groupneous LF15-0195 treatment is effective in suppressing
the induction of rat anti-GBM disease and the progres- was killed at day 7 in this experiment to determine the
extent of kidney pathology prior to treatment. In experi-sion of established disease. Our assessment included an
analysis of both humoral and cellular immune responses ment 2b, groups were administered with either saline or
LF15-0195 (4 mg/kg/day) from days 7 to 12 and wereand a comparison between continuous LF15-0195 treat-
ment and short-term “pulse” therapy. killed at day 28. Two hours prior to being killed, all rats
received an intraperitoneal injection of saline containing
bromodeoxyuridine (BrdU; 50 mg/kg), which incorpo-
METHODS
rated into proliferating cells.
Materials In addition, a skin delayed-type hypersensitivity (DTH)
response was assessed in groups of eight rats. AnimalsLF15-0195 was provided by Fournier Laboratoires
(Daix, France). Enzyme-linked immunosorbent assay were primed with 5 mg sheep IgG in FCA and challenged
14 days later with intradermal injections of 100 g of(ELISA) kits detecting rat interleukin-1 (IL-1; Endo-
gen, Woburn, MA, USA) and rat transforming growth sheep IgG and bovine serum albumin (BSA). Two hours
prior to antigen challenge, rats received a single subcuta-factor-1 (TGF-1; Promega, Madison, WI, USA) were
used for urine cytokine analysis. Monoclonal antibodies neous injection of either saline or LF15-0195 (4 mg/kg).
Skin swelling at the antigen injection site was measured(mAbs) used in this study were OX-1, anti-rat CD45R
(leukocyte common antigen); ED1, anti-rat CD68 (macro- by micrometer calipers after 24 hours.
phage-specific antigen); R73, anti-rat T-cell receptor (non-
Hematology assessmentpolymorphic determinant); NDS-61 and OX-39, anti-rat
CD25 (IL-2 receptor -chain); 1A4, anti--smooth mus- Whole blood cell counts were performed on a Cell-
Dyn 3500 automated cell counter (Abbott Laboratories,cle actin (Sigma, St. Louis, MO, USA); HWD1.1, anti-
collagen III (BioGenex, San Ramon, CA, USA); Bu20a, Abbot Park, IL, USA) using heparinized blood collected
from tail veins.anti-bromodeoxyuridine (Dako, Carpinteria, CA, USA);
and 73.5, anti-human CD45, which does not react with
Biochemical analysis of blood and urinerat tissues. Polyclonal primary antibodies used in this
study were fluorescein isothiocyanate (FITC)-conjugated Urine was collected over 24 hours from rats housed in
metabolic cages. Serum was collected from whole bloodrabbit anti-sheep Ig, FITC-conjugated rabbit anti-rat IgG,
and FITC-conjugated rabbit anti-rat C3 (all from Sigma). obtained from the tail vein of anesthetized rats. Urine
protein, urine creatinine, and serum creatinine were ana-Antibodies not purchased from commercial sources were
produced by cell culture of hybridomas obtained from lyzed by the Department of Biochemistry at the Monash
Medical Centre. Commercial ELISA kits were used tothe European collection of cell cultures (ECACC).
measure IL-1 (Endogen) and total TGF-1 (Promega)
Animal model and treatment in rat urine samples. The levels of anti-sheep IgG in rat
serum were analyzed by ELISA as previously describedMale inbred Sprague-Dawley rats were obtained from
Monash Animal Services (Melbourne, Australia). Anti- [15].
GBM disease was induced in Sprague-Dawley rats as
Immunohistochemistrypreviously described [16]. Briefly, rats were immunized
with 5 mg of normal sheep IgG in Freund’s complete Kidney deposition of sheep Ig, rat IgG, and comple-
ment C3 were detected on unfixed cryostat tissue sec-adjuvant (FCA) and injected intravenously with sheep
anti-rat GBM serum seven days later. Disease was in- tions (4 m) by immunofluorescence staining with FITC-
conjugated rabbit polyclonal antibodies. Semiquantita-duced in groups of eight rats that received daily subcuta-
neous injections of either normal saline or LF15-0195 tion of immunofluorescence staining was performed by a
blinded antibody titration method [15]. Immunostainingaccording to the experimental protocol. Experiments
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for kidney leukocytes, proliferating cells, myofibroblasts
and collagen was performed with monoclonal antibodies
on either paraformaldehyde-lysine-periodate (PLP) fixed
cryostat sections (6 m) or formalin-fixed paraffin sec-
tions (4 m) using a three antibody layer immuno-peroxi-
dase or immuno-alkaline phosphatase detection method,
as previously described [17]. Sections immunostained for
leukocytes and proliferating cells were counterstained
with periodic acid-Schiff (PAS) reagent. The number of
glomerular leukocytes was counted under high power
(400) in 20 glomerular cross-sections per animal. The
number of interstitial leukocytes in the cortex was deter- Fig. 1. LF15-0195 does not affect glomerular deposition of antibody
or complement C3 during anti-glomerular basement membrane (GBM)mined by counting the number of stained cells in 30
disease. Glomerular deposition of sheep Ig, rat IgG, and rat C3 wereconsecutive high-power fields (250) by means of a 0.02
detected by immunofluoresence staining of kidney sections at day 14
mm2 graticule fitted in the eyepiece of the microscope. of disease. Serial antibody dilutions (twofold) were used to determine
the end point of immunofluorescence. LF15-0195 treatment did notThese fields progressed from the outer to inner cortex,
affect the deposition of Ig or C3. Data are mean  SD, N  8. Symbolsavoiding only large vessels, glomeruli, and immediate
are: () saline; ( ) LF15-0195.
periglomerular areas. No adjustment of the cell count
was made for tubules or the luminal space. Proliferating
tubular cells labeled with BrdU were assessed by count- mild lesions; 2  intermittent moderate lesions; and 3 
ing the number of stained nuclei in 500 randomly selected frequent severe lesions.
cortical tubules per section. Kidney cortex expression of
collagen III and -smooth muscle actin was recorded by Statistical analysis
digital camera and evaluated as a percentage of area
Statistical differences between two comparative groupsimmunostained using image analysis software (Image J;
were analyzed by the unpaired Student t test (parametricResearch Services Branch, National Institute of Mental
data) or the Mann-Whitney test (nonparametric data).Health, Bethesda, MD, USA). Glomerular staining and
Data was recorded as the mean  standard deviationconstitutive expression of -smooth muscle actin and
(SD) and values of P 	 0.05 were considered significant.collagen by kidney vessels was excluded from the image
All of the analyses were performed using the statisticalassessment.
software in GraphPad Prism 3.0 (GraphPad Software,
San Diego, CA, USA).Pathology assessment
Kidney pathology was assessed on 3 m paraffin sec-
tions of formalin-fixed tissues stained with PAS and he- RESULTS
matoxylin. Histopathology scoring was performed on
LF15-0195 treatment prevents the induction ofblinded slides by a pathologist. Segmental glomerular
anti-GBM diseaselesions (proliferation/necrosis/sclerosis) were assessed in
50 glomeruli/kidney by scoring the glomerular area af- In this rat model of anti-GBM disease, induction of
renal injury involves the glomerular deposition of sheepfected: 0  none; 1  1 to 25%; 2  25 to 50%; 3  50
to 75%; and 4 75 to 100%. Glomerular crescents were anti-GBM antibody followed by deposition of comple-
ment and rat IgG. Immunofluorescence staining at daydefined as two or more cell layers within Bowman’s space
and were evaluated as the percentage of glomeruli with 14 of anti-GBM disease showed similar glomerular levels
of sheep Ig, rat IgG, and complement C3 deposited increscents per kidney. Tubulointerstitial lesions were de-
termined by the expansion of the interstitial area and saline-treated and LF15-0195–treated rats (Fig. 1). In
contrast, serum obtained from LF15-0195–treated ratsdamage to tubules (tubulitis, dilation, atrophy, casts) and
were graded as follows: 0  no lesions; 1  occasional at day 14 of disease had reduced levels of anti-sheep Ig

Fig. 2. LF15-0195 suppresses white blood cell (WBC) numbers during anti-GBM disease. Symbols are: () saline; () LF15-0195. WBCs
(lymphocytes, neutrophils, monocytes) were increased in saline-treated rats following the induction of anti-GBM disease. Daily LF15-0195 treatment,
commencing at the induction of disease (experiment 1), reduces the rise in WBC counts at days 7 and 14 compared with saline (A–D). Continuous
intervention treatment with LF15-0195, beginning at day 7 of disease (experiment 2a), reduces the neutrophils and monocytes compared to saline
treatment (E–H). Pulse treatment with LF15-0195 from days 7 to 12 (experiment 2b) temporarily reduces the neutrophils and monocytes at day
14 of disease compared with saline (J–L). Data are mean  SD, N  8; *P 	 0.005 vs. saline-treated.
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Fig. 3. LF15-0195 inhibits proteinuria and loss of renal function in anti-GBM disease. Daily LF15-0195 treatment from the initiation of anti-GBM
disease prevents the development of proteinuria (A) and the decline in creatinine clearance (CCr) (B) associated with disease progression. LF15-
0195 treatment beginning at day 7 of anti-GBM disease inhibits the progressive increase in proteinuria (C) and provides some resistance against
the progressive reduction in creatinine clearance (D). Data are mean  SD, N  8; *P 	 0.05; **P 	 0.005 vs. saline treated. Symbols are: ()
saline treated; () LF15-0195 (in A and B) or continuous LF15-0195 (in C and D); () pulse LF-15-0195.
(↓60%, P	 0.05) compared with saline-treated rats (data nificant numbers of glomerular and interstitial infiltrating
cells (Figs. 4A and 5 A–C). In comparison, rats thatnot shown).
During the induction of anti-GBM disease, circulating received LF15-0195 during disease induction showed al-
most no evidence of kidney pathology (Figs. 4B and 5white blood cells (WBCs) were increased by 40 to 80%
in rats given saline treatment (Fig. 2A). In comparison, A–C). These rats had histologically normal glomeruli
and tubules and few infiltrating cells in the interstitium.LF15-0195–treated rats had reduced numbers of WBCs
at days 7 and 14 that were similar to normal (Fig. 2A). The accumulation of kidney-infiltrating leukocytes, myo-
fibroblasts, and extracellular matrix was associated withFurther analysis indicated that LF15-0195 reduced the
increased numbers of blood lymphocytes, neutrophils, the development of anti-GBM disease in saline-treated
rats. LF15-0195 largely suppressed the glomerular andand monocytes at days 7 and 14 compared with saline
treatment; however, only monocytes were reduced by interstitial leukocyte infiltrate seen in saline-treated kid-
neys at day 14 (Figs. 4D and 6). Similarly, LF15-0195LF15-0195 compared with normal animals (Fig. 2 B–D).
Induction of anti-GBM disease resulted in the rapid prevented the appearance of -smooth muscle actin–
labeled myofibroblasts in the interstitial and periglomer-development of proteinuria and a reduction in creatinine
clearance in saline-treated rats, which was prevented by ular regions of the kidney (Fig. 4 E, F) and an increased
interstitial expression of collagen type III at day 14 com-LF15-0195 treatment (Fig. 3 A, B). At day 14, saline-
treated rats had moderate histological kidney damage, pared with normal animals (microscopy observations).
Significant levels of IL-1 (2.01  0.96 pg/24 h) andincluding segmental glomerular proliferative lesions, glo-
merular sclerosis with occasional glomerular crescents, TGF- (3.11  1.52 pg/24 h) appeared in the urine of
saline-treated rats at day 14 of anti-GBM disease, butdilated and atrophic tubules with protein casts, and sig-
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Fig. 4. LF15-0195 suppresses renal pathology during the induction of rat anti-GBM disease. Kidney sections stained with PAS and hematoxylin
show the development of histological lesions in saline-treated rats at day 14 during the induction of anti-GBM disease (A), which were largely
suppressed in rats that received LF15-0195 treatment (B). Immunoperoxidase staining of saline-treated rats shows infiltrating OX-1 kidney
leukocytes at day 14 (C ), which were reduced by LF15-0195 treatment (D). Kidney myofibroblasts expressing -smooth muscle actin in saline-
treated rats at day 14 (E ) were diminished by LF15-0195 treatment (F ). Constitutive expression of -smooth muscle actin in kidney vessels is
indicated by arrowheads (E and F). Magnification A–F, 100.
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Fig. 6. LF15-0195 reduces kidney leukocyte accumulation in anti-GBM
disease. Immunoperoxidase staining with OX-1 antibody was used to
detect kidney leukocytes during anti-GBM disease. Increased numbers
of leukocytes per glomerular cross-section (gcs) were detected in saline-
treated rats at day 14 of disease compared with normal rats and were
reduced to near-normal levels by daily LF15-0195 treatment commenc-
ing at the initiation of disease (A). LF15-0195 treatment similarly de-
creased the numbers of interstitial leukocytes at day 14 of disease (B).
Data are mean  SD; N  8; *P 	 0.01; **P 	 0.001.
were not detected in normal rat urine. LF15-0195 mark-
edly reduced the urine levels of IL-1 (↓61%, 0.79 
0.70 pg/24 h, P 	 0.05) and TGF- (↓95%, 0.17  0.49
pg/24 h, P 	 0.005) at day 14 compared with saline
treatment.
LF15-0195 inhibits the delayed-type
hypersensitivity response
A single dose of LF15-1095 administered 2 hours be-
fore a skin DTH antigen challenge inhibited the 24-hour
skin swelling in response to sheep IgG (2.42  0.15 mm,
↓17%, P 	 0.05) compared with saline treatment (2.91 
Fig. 5. LF15-0195 reduces histological lesions in anti-GBM disease.
0.15 mm). Blood measurements at the time of skin DTHDuring the induction of anti-GBM disease, LF15-0195 treatment mark-
edly inhibited the appearance of segmental glomerular lesions (A), assessment indicated that WBC levels were not affected
glomerular crescents (B), and tubular/interstitial disease (C) at day 14 by LF15-0195 (16.3  0.9 K/L WBC) compared with
compared with saline-treated rats (experiment 1). Between days 7 and
saline treatment (17.6  1.5 K/L WBC).28 of disease, there was an increase in glomerulosclerosis (D) and
crescent formation (E ), which was reduced by LF15-0195 intervention
treatment (experiment 2). There was a semiquantitative increase in LF15-0195 suppresses the progression of established
tubular/interstitial disease between days 7 and 28; however, LF15-0195 anti-GBM diseasetreatment did not significantly reduce this score (F ). Data are mean 
SD, N  8. Symbols are: () saline; ( ) pulse LF15-0195; ( ) continu- At day 7 of anti-GBM disease, prior to the commence-
ous LF15-0195; () untreated; *P 	 0.05; **P 	 0.01; ***P 	 0.001. ment of intervention therapy, rats had developed ele-
vated WBC (Fig. 2 E, I), proteinuria (Fig. 3C), reduced
creatinine clearance (Fig. 3D), glomerular and interstitial

Fig. 7. LF15-0195 treatment of established anti-GBM disease inhibits the progression of renal pathology. Immunoperoxidase staining in anti-
GBM kidneys showing (A) ED1 macrophages and (E) myofibroblasts labeled with -smooth muscle actin (SMA) at day 7, prior to intervention
treatment. (B) Macrophages and (F ) myofibroblasts at day 28 following saline-treatment. (C) Macrophages and (G) myofibroblasts at day 28
following continuous LF15-0195 treatment. (D) Macrophages and (H ) myofibroblasts following pulse LF15-0195 treatment. Magnification A–D,
100, and E–H, 20).
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Fig. 8. LF15-0195 treatment of established anti-GBM disease suppresses the progressive accumulation of interstitial leukocytes. Immunoperoxidase
staining was used to detect kidney macrophages (ED1), T cells (R73), and IL-2R cells (NDS-61) during anti-GBM disease. Glomerular
leukocytes consisted of almost entirely macrophages at day 7 of disease and did not increase by day 28. Glomerular macrophages were only
marginally reduced by LF15-0195 treatment (A). In comparison, interstitial macrophages (B), T cells (C), and IL-2R cells (D) were all significantly
increased between days 7 and 28 on disease. LF15-0195 treatment markedly suppressed the increase in these interstitial leukocytes (B–D). Data
are mean  SD; N  8. Symbols are: () continuous LF15-0195; () pulse LF15-0195; () saline; *P 	 0.05 vs. day 28 saline-treated; #P 	 0.05
vs. day 7.
histological lesions (Fig. 5 D–F), a striking kidney macro- of creatinine clearance between days 7 and 28 and was
significantly better than saline-treated rats at day 28.phage infiltrate (Figs. 7A and 8 A, B), and a significant
interstitial accumulation of myofibroblasts and collagen LF15-0195 pulse therapy was able to restore normal cre-
atinine clearance at day 14, which thereafter declinedtype III (Figs. 7B and 10).
Compared with saline-treated rats, those that received and was not different to saline-treated rats at days 21
and 28.LF15-0195 continuously from days 7 to 28 of anti-GBM
disease had reduced blood levels of neutrophils and In saline-treated rats at day 28, glomerular and intersti-
tial lesions had progressed from moderate to severe.monocytes, but not lymphocytes, at days 14, 21, and 28
(Fig. 2 E–H). Similarly, a five-day pulse treatment with Crescents were observed in 16% of glomeruli, and infil-
trating cells were significantly increased in the intersti-LF15-0195 from days 7 to 12 lowered the numbers of
blood neutrophils and monocytes at day 14 compared tium (Fig. 5 D–F). Both continuous and pulse LF15-
0195 treatments inhibited the progression of histologicalwith saline treatment; however, all WBCs subsequently
returned to the same level as saline-treated rats at day lesions between days 7 and 28 (Fig. 5 D–F), resulting in
reduced sclerosis and fewer glomerular crescents.21 (Fig. 2 I–H).
LF15-0195 intervention treatment partially inhibited Between days 7 and 28 of anti-GBM disease, there was
no increase in glomerular leukocytes, which consistedthe progressive increase in proteinuria and decrease in
creatinine clearance that occurred between days 7 and of mostly macrophages (
90%). Intervention treatment
with LF15-0195 had little or no effect on glomerular28 in saline-treated rats (Fig. 3 C, D). Both continuous
and pulse LF15-0195 treatments were effective. Continu- macrophage accumulation (Figs. 7 A–D and 8A). In con-
trast, there was a significant increase in the number ofous LF15-0195 treatment prevented a progressive loss
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Fig. 9. LF15-0195 reduces tubular proliferation in established anti-
GBM disease. Injured kidney tubules with proliferating epithelial cells
were detected by immunostaining for bromodeoxyuridine (BrdU),
which was injected into rats prior to killing. Continuous and pulse
LF15-0195 treatment reduced the number of proliferating tubular cells
compared with saline-treated animals. Data are mean  SD, N  8.
Symbols are: () continuous LF15-0195; () pulse LF15-0195; ()
saline; *P 	 0.01 vs. day 28 saline treated; #P 	 0.05 vs. day 7.
macrophages, T cells and IL-2 receptor cells within the
interstitium in saline-treated rats between days 7 and 28,
which was markedly reduced by both pulse and continu-
ous LF15-0195 treatment (Fig. 8 B–D).
Compared with normal rats, those with anti-GBM dis- Fig. 10. LF15-0195 reduces the progression of interstitial fibrosis in
established anti-GBM disease. Fibrosis in the interstitium of kidneysease had a marked increase in tubular cell proliferation
with anti-GBM disease was detected by immunoperoxidase staining forat day 7, which was maintained through to day 28 (Fig. 9).
-smooth muscle actin in myofibroblasts (A) and interstitial collagen
Both continuous and pulse LF15-0195 treatment reduced type III (B). Pulse and continuous LF15-0195 intervention treatment
prevented the progressive increase in interstitial -smooth muscle actinthe number of proliferating BrdU tubular cells at day
expression between days 7 and 28. Pulse LF15-0195 treatment reduced28 compared with saline-treated rats. In addition, rats
collagen type III staining in the renal cortex at day 28 compared with
treated continuously with LF15-0195 from day 7 had saline treatment. Data are mean  SD, N  8. Symbols are: ()
continuous LF15-0195; () pulse LF15-0195; () saline; *P 	 0.0005fewer proliferating tubular cells at day 28 than at day 7
vs. day 28 saline-treated; #P 	 0.05 vs. day 7.before treatment began.
Continuous and pulse LF15-0195 treatment prevented
the increase in interstitial -smooth muscle actin expres-
sion observed in saline-treated animals between days ment (3.92 1.32 pg/24 h). Urine IL-1 levels decreased
7 and 28 (Fig. 10A). Compared with saline treatment, between days 7 (3.50  1.55 pg/24 h) and 28 (2.01 
interstitial deposition of collagen type III was signifi- 1.39 pg/24 h, P 	 0.05) and were not reduced at day 28
cantly reduced by pulse, but not continuous, LF15-0195 compared with saline treatment by either continuous
treatment at day 28 (Fig. 10B). LF15-0195 treatment (2.39 1.84 pg/24 h) or pulse LF15-
Following the initiation of LF15-0195 intervention 0195 treatment (2.37  0.75 pg/24 h).
treatment, there was a reduction of serum anti-sheep
IgG observed at day 14 in both pulse and continuous
DISCUSSIONtreatment groups. However, the anti-sheep IgG level in
the pulse treatment group returned to the same level as Our results demonstrate that LF15-0195 treatment can
prevent the development of rat anti-GBM disease andthe saline-treated group at day 21, while continuous
LF15-0195 treatment maintained serum anti-sheep IgG can suppress the progression of this disease once it is
already established. LF15-0195 averted the induction ofat the low level observed at day 14 (Fig. 11).
Urine TGF- levels did not increase in saline-treated anti-GBM disease by preventing the onset of proteinuria,
loss of renal function, kidney leukocyte infiltration, theanimals between days 7 (3.40  1.53 pg/24 h) and 28
(4.49  1.17 pg/24 h) of anti-GBM disease and were development of histological lesions, and renal fibrosis.
Continuous LF15-0195 treatment during disease in-not reduced at day 28 by either continuous LF15-0195
treatment (3.94 1.91 pg/24 h) or pulse LF15-0195 treat- duction reduced the serum levels of rat anti-sheep anti-
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phages and T cells and subsequent tubular proliferation
and renal fibrosis. This effect may be largely attributable
to the suppression of interstitial leukocyte accumulation
and activation, since macrophages and T cells can pro-
mote tubular injury and fibrotic responses, and their
accumulation in the interstitium during kidney disease
correlates with tubular responses to injury (that is, cell
proliferation and apoptosis) and the development of re-
nal fibrosis [18–21]. However, LF15-0195 also may have
direct inhibitory effects on tubular and fibrotic responses
within the kidney that could account for the reduction
in tubular cell proliferation and -smooth muscle actin
expression following LF15-0195 treatment. The structur-
ally related drug, deoxyspergualin, has been shown to
Fig. 11. LF15-0195 reduces serum antibodies in established anti-GBM inhibit the proliferation of mesangial cells [14], and there-disease. Serum levels of antibody against sheep IgG were determined
fore, LF15-0195 may suppress the proliferation of inter-by ELISA. The level of anti-sheep antibodies remained constant be-
tween days 7 and 28 in saline-treated rats. In comparison, rats that stitial myofibroblasts or tubular epithelial cells through
received continuous LF15-0195 treatment or pulse LF15-0195 treatment similar mechanisms. Studies have shown that the pro-from day 7 had reduced serum antibodies at day 14. The reduction in
gression of renal injury during kidney disease is associ-serum antibodies was maintained in rats receiving continuous LF15-
0195, while serum antibodies in pulse-treated rats returned to the same ated with the proliferation of tubular cells [22, 23] and
level as saline-treated at day 21. Data are mean  SD; N  8. Symbols the accumulation of interstitial myofibroblasts [24–27],are: () continuous LF15-0195; () pulse LF15-0195; () saline; *P 	
indicating that LF15-0195–mediated inhibition of renal0.001 vs. saline treated.
cell proliferation may be an important component in its
suppression of the progression of kidney disease.
An interesting finding was that animals receiving pulse
body at day 14, but did not significantly affect the glomer- or continuous LF15-0195 treatment had similar reduc-
ular deposition of sheep IgG, rat IgG, and C3. This tions in some of the criteria used to assess the severity
suggests that the ability of LF15-0195 to prevent the of renal disease (that is, proteinuria, leukocyte and myo-
induction of disease is not due to the prevention of the fibroblast accumulation, tubular cell proliferation, cres-
humoral response to glomerular deposited sheep IgG, cent formation). The similarities of outcomes between
but rather may reflect a suppression of a developing cell- the pulse and continuous therapeutic strategies suggest
mediated immune response. We noted that continuous that prolonged suppression of bone marrow associated
LF15-0195 treatment decreased the levels of blood with continuous LF15-0195 treatment may not be neces-
monocytes and neutrophils in rats at day 14; however, sary for achieving an optimal reduction in kidney disease.
this reduction was not seen during the first 24 hours of Of the immunosuppressants that have been used to
treatment when induction of anti-GBM disease causes treat the induction of anti-GBM disease, LF15-0195 ap-
significant proteinuria, suggesting that LF15-0195 pre- pears to offer the greatest protection against renal injury.
vention of disease induction is not due to blood leukocyte In comparison, treatment with deoxyspergualin can pre-
depletion. Although it is not clear why LF15-0195 pre- vent a loss of renal function and suppress histological
vents the induction of rat anti-GBM disease, one possible lesions, but only partially prevents proteinuria during
explanation may be that LF15-0195 prevents the kidney the induction of anti-GBM disease [15]. CsA and FK506
recruitment and activation of leukocytes, which cause can inhibit the development of accelerated anti-GBM
the initial glomerular injury resulting in proteinuria. This disease when given prior to the Ig preimmunization.
concept is supported by our finding that LF15-0195 treat- However, CsA treatment, after establishment of the anti-
ment inhibits a skin DTH response without depleting body response, fails to alter the disease outcome [28, 29].
WBC. In addition, a lack of urine IL-1 and TGF- LF15-0195 is the first immunosuppressant that has
in LF15-0195–treated animals during induction of anti- been shown to be effective at suppressing the progression
GBM disease suggests that cytokines that can promote of established anti-GBM disease. Intervention treatment
leukocyte-mediated tissue injury and fibrosis may not be of accelerated anti-GBM disease with either azathio-
present at high enough levels within the kidney to have prine or methylprednisolone can partially reduce pro-
pathological significance. teinuria and the humoral response, but is ineffective at
LF15-0195 treatment of established anti-GBM disease reducing the development of histological lesions [30].
inhibited the progression of renal injury (increased pro- FK506, mycophenylate mofetil, and DSG are able to
teinuria and decreased creatinine clearance) by sup- suppress partially the progression of established kidney
disease in lupus mice [31–33], but it is not clear whetherpressing the kidney interstitial accumulation of macro-
Tesch et al: LF15-0195 suppresses anti-GBM nephritis 1365
14. Nikolic-Paterson DJ, Tesch GH, Lan HY, et al: Deoxyspergualinthese immunosuppressants would be effective in pre-
inhibits mesangial cell proliferation and major histocompatibility
venting the progression of the rapidly developing lesions complex class II expression. J Am Soc Nephrol 5:1895–1902, 1995
associated with anti-GBM disease. 15. Lan HY, Zarama M, Nikolic-Paterson DJ, et al: Suppression of
experimental crescentic glomerulonephritis by deoxyspergualin.In conclusion, the immunosuppressant LF15-0195 is
J Am Soc Nephrol 3:1765–1774, 1993capable of suppressing the progression of established 16. Lan HY, Paterson DJ, Atkins RC: Initiation and evolution of
kidney disease and the loss of renal function during the interstitial leukocyte infiltration in experimental glomerulonephri-
tis. Kidney Int 40:425–433, 1991development of accelerated rat anti-GBM nephritis. This
17. Lan HY, Nikolic-Paterson DJ, Atkins RC: A novel, simple,finding suggests that LF15-0195 is a promising therapeu- reliable, and sensitive method for multiple immunoenzyme stain-
tic reagent for the potential treatment of human glomer- ing: Use of microwave oven heating to block antibody crossreactiv-
ity and retrieve antigens. J Histochem Cytochem 43:97–102, 1995ulonephritis.
18. Hooke DH, Gee DC, Atkins RC: Leukocyte analysis using mono-
clonal antibodies in human glomerulonephritis. Kidney Int 31:964–
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